Effects of random glucose (Glc) levels on outcomes of patients (pts) with pancreatic ductal adenocarcinoma (PDAC)

Rille Pihlak, Rose Almond, Prakhar Srivastava, Haseem Raja, Rachel Broadbent, Louise Hopewell, C Higham, Angela Lamarca, Richard Hubner, Juan W Valle, Mairead Mcnamara

Research output: Contribution to conferenceAbstractpeer-review


Background Pancreatic ductal adenocarcinoma is a dismal disease with poor outcomes; ∼85% of pts with PDAC have impaired Glc tolerance or diabetes. This study explored how random Glc levels influence pt outcomes. Methods Consecutive pts with PDAC (all stages) (Jan 12-Jul 17) were included; 3 blood Glc level thresholds were referenced: >8 mmol/L (requiring monitoring), ≥14 mmol/L (requiring antidiabetic treatment), >11mmol/L on 2 occasions (fulfilling WHO diabetes criteria). Survival outcomes/prognostic factors were analysed by log-rank, Kaplan Meier and multivariable Cox regression. Results Of 640 pts: 53 % were male, median (med) age 68y, 64% ECOG PS 0/1, 22% PS 2, 14% PS 3/4; 26% stage 1/2 disease, 74% stage 3/4; 81% treated with palliative intent (chemotherapy in 325) and 15% adjuvant; 29% pts had a previous diabetes diagnosis. Med baseline Glc: 7.3mmol/L (range 3.8-37.1); 377 (59%) and 145 (23%) pts had Glc >8mmol/L and ≥14 mmol/L respectively, either at baseline or during treatment, 124 (19%) had Glc >11mmol/L on 2 occasions (of whom 81 were known diabetic). Med PFS and OS for all stages were 6.7 (95%CI 6.0-7.1) and 8.1 (95%CI 7.4-8.8) months (mo) respectively. Med OS for stage 1/2: 11.3 mo (95%CI 9.4-13.8), stage 3/4 disease 5.3 mo (95%CI 4.8-6). Previous diabetes diagnosis and antidiabetic treatment did not significantly impact OS (P = 0.26, P = 0.5 respectively). Baseline Glc levels (>8mmol/L and ≥14 mmol/L; Table), but not hyperglycaemia during treatment, significantly affected OS in all pts. Multivariable analysis (once adjusted for age and primary site) found increasing stage (P < 0.001), high minimum Glc (ever)(P < 0.001), high CA19-9 (P < 0.001), worse ECOG PS (P < 0.01) , and low albumin (P = 0.02) were prognostic for worse OS. Table: 751P Conclusions This study demonstrated for the first time that baseline Glc above thresholds and the absolute minimum random Glc confers worse outcomes, irrespective of previous diabetes diagnosis. Whether this risk is modifiable is subject to further research.
Original languageEnglish
Publication statusPublished - 21 Oct 2018


  • Pancreas cancer
  • Glucose control
  • Survival

Research Beacons, Institutes and Platforms

  • Manchester Cancer Research Centre


Dive into the research topics of 'Effects of random glucose (Glc) levels on outcomes of patients (pts) with pancreatic ductal adenocarcinoma (PDAC)'. Together they form a unique fingerprint.

Cite this